

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
02 July 2020 (02.07.2020)



(10) International Publication Number
WO 2020/139636 A1

(51) International Patent Classification:

C07D 401/14 (2006.01) A61K 31/4439 (2006.01)
C07D 401/12 (2006.01) A61K 31/4155 (2006.01)
C07D 405/14 (2006.01) A61K 31/41 (2006.01)
C07D 213/74 (2006.01) A61P 35/00 (2006.01)
A61K 31/444 (2006.01)

(21) International Application Number:

PCT/US2019/066993

(22) International Filing Date:

17 December 2019 (17.12.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/785,616 27 December 2018 (27.12.2018) US

(71) Applicant: **NEXYS THERAPEUTICS, INC.** [US/US];
10210 Campus Point Drive, Suite 150, San Diego, CA
92121 (US).

(72) Inventors: **WU, Tom Yao-hsiang**; 17570 Teal Stone
Court, San Diego, CA 92127 (US). **JIN, Qihui**; 7885 Stylus
Drive, San Diego, CA 92108 (US).

(74) Agent: **SMITH, Michael** et al.; Rimon, P.C., One Embar-
cadero Center, Suite 400, San Francisco, CA 94111 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))


Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(54) Title: (PYRIDIN-2-YL)AMINE DERIVATIVES AS TGF-BETA R1 (ALK5) INHIBITORS FOR THE TREATMENT OF CAN-
CER



Formula (I)



Formula (II)

(57) Abstract: The present invention relates to pharmaceutical compounds, compositions and methods, especially as they are related to compositions and methods for the treatment and/or prevention of a proliferation disorder associated with TGFβR1 activity, such as a cancer or fibrosis. The invention provides compounds of Formula (I) and Formula (II) as further described herein having an acidic moiety that enhances tissue specificity for targeted tissues and organs. The invention includes pharmaceutical compositions, pharmaceutical combinations, and methods of use of these compounds for treating conditions including cancer or fibrosis.